ArticleACS omega2020
UPLC-Q-TOF/MS-Based Serum Metabolomics Reveals the Anti-Ischemic Stroke Mechanism of Nuciferine in MCAO Rats.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Insights into nuciferine: A natural multifunctional bioactive alkaloid (Review).Molecular medicine reports · 2026Review
- High-Resolution Spatiotemporal Mapping of Cerebral Metabolism During Middle-Cerebral-Artery Occlusion/Reperfusion Progression: Preliminary Insights.Biomolecules · 2025Article
- The effect of nuciferine on the renal dysfunction following ischemia-reperfusion injury.PloS one · 2025Article
- Pharmacological effects and target analysis of Guipi wan in the treatment of cerebral ischemia-reperfusion injury.Frontiers in pharmacology · 2024Article
- Metabolomics: A useful tool for ischemic stroke research.Journal of pharmaceutical analysis · 2023Review
- Nuciferine Effectively Protects Mice against Acetaminophen-Induced Liver Injury.Antioxidants (Basel, Switzerland) · 2023Article
- Repurposing the mucolytic agent ambroxol for treatment of sub-acute and chronic ischaemic stroke.Brain communications · 2023Article
- Metabolomics of ischemic stroke: insights into risk prediction and mechanisms.Metabolic brain disease · 2022Review
- Protective Effects of Nuciferine in Middle Cerebral Artery Occlusion Rats Based on Transcriptomics.Brain sciences · 2022Article
- Isolation and Characterization of Natural Nanoparticles in Naoluo Xintong Decoction and Their Brain Protection Research.Molecules (Basel, Switzerland) · 2022Article
- Nuciferine Regulates Immune Function and Gut Microbiota in DSS-Induced Ulcerative Colitis.Frontiers in veterinary science · 2022Article
- Metabolomics-Based Pharmacodynamic Analysis of Zhuang Yao Shuang Lu Tong Nao Granules in a Rat Model of Ischemic Cerebral Infarction.Analytical cellular pathology (Amsterdam) · 2022Article
- Involvement of Ceramide Metabolism in Cerebral Ischemia.Frontiers in molecular biosciences · 2022Review
- Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome.Molecules (Basel, Switzerland) · 2021Review
- Synergic Neuroprotection BetweenFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuciferine is an aporphine alkaloid monomer that is extracted from the leaves of the lotus species
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.